You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
No AccessJournal of UrologyAdult Urology1 Nov 2018

The Association of Previous Prostate Biopsy Related Complications and the Type of Complication with Patient Compliance with Rebiopsy Scheme

    View All Author Information


    Prostate biopsy complications have important consequences that may affect patient compliance with rebiopsy schemes. However, to our knowledge this has not been studied in earnest. Thus, we evaluated whether previous prostate biopsy related complications and the type of complication were associated with repeat prostate biopsy compliance in a clinical trial with study mandated systematic biopsies.

    Materials and Methods:

    We retrospectively analyzed the records of 4,939 men 50 to 75 years old who underwent 2-year prostate biopsy and were recommended to undergo 4-year prostate rebiopsy in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) study. The analyzed biopsy complications were hematuria, urinary tract infection, acute urinary retention and hemospermia.


    A total of 260 men (5.3%) had a 2-year prostate biopsy related complication, including hematuria in 180 (3.6%), urinary tract infection in 36 (0.7%), acute urinary retention in 26 (0.5%) and hemospermia in 102 (2.1%). A total of 474 men (9.6%) were noncompliant with 4-year rebiopsy. On univariable analysis any previous complication (OR 1.56, 95% CI 1.08–2.24, p = 0.018), urinary tract infection (OR 2.72, 95% CI 1.23–6.00, p = 0.013), acute urinary retention (OR 4.24, 95% CI 1.83–9.81, p = 0.016) and hemospermia (OR 1.78, 95% CI 1.03–3.06, p = 0.037) were associated with rebiopsy noncompliance. Hematuria was not associated with rebiopsy noncompliance (OR 1.19, 95% CI 0.74–1.91, p = 0.483). Results were unchanged on multivariable analysis, including for any complication (OR 1.65, 95% CI 1.08–2.26, p = 0.018), for urinary tract infection (OR 2.62, 95% CI 1.07–3.21, p = 0.029), for acute urinary retention (OR 4.51, 95% CI 1.93–10.54, p = 0.001), for hemospermia (OR 1.85, 95% CI 1.07–3.21, p = 0.029) and for hematuria (OR 1.19, 95% CI 0.74–1.93, p = 0.472).


    In men who undergo repeat prostate biopsy a previous biopsy related complication and the type of complication were associated with lower compliance with rebiopsy schemes. Patients who experience biopsy related complications are ideal candidates to receive intervention regarding the importance of prostate rebiopsy to prevent noncompliance.


    • 1 : Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol2006; 175: 1605. LinkGoogle Scholar
    • 2 : Repeat prostate biopsy: rationale, indications, and strategies. Eur Urol Focus2015; 1: 127. Google Scholar
    • 3 : Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis2010; 13: 71. Google Scholar
    • 4 : Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy. PloS One2013; 8: e57480. Google Scholar
    • 5 : Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE. Prostate Cancer Prostatic Dis2016; 19: 202. Google Scholar
    • 6 : Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol2010; 183: 963. LinkGoogle Scholar
    • 7 : Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol2013; 63: 521. Google Scholar
    • 8 : Complications after systematic, random, and image-guided prostate biopsy. Eur Urol2017; 71: 353. Google Scholar
    • 9 : Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol2015; 68: 814. Google Scholar
    • 10 : Complications after prostate biopsy: data from SEER-Medicare. J Urol2011; 186: 1830. LinkGoogle Scholar
    • 11 : Effect of dutasteride on the risk of prostate cancer. N Engl J Med2010; 362: 1192. Google Scholar
    • 12 : Randomised trial of prostate cancer screening in The Netherlands: assessment of acceptance and motives for attendance. J Med Screen1997; 4: 102. Google Scholar
    • 13 : Why do men refuse or attend population-based screening for prostate cancer?. J Public Health Med2000; 22: 312. Google Scholar
    • 14 : Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology2002; 60: 846. Google Scholar
    • 15 : Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther2001; 26: 331. Google Scholar
    • 16 : Association between literacy, compliance with prostate cancer screening, and cancer aggressiveness: results from a Brazilian screening study. Int Braz J Urol2013; 39: 328. Google Scholar
    • 17 : Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA2006; 296: 2563. Google Scholar